26 May 2013
Keywords: MRSA, Theravance, Astellas, J&J, Basilea, AstraZeneca, Takeda, Market
Article | 24 November 2009
Over the next decade, modest growth in the methicillin-resistant Staphylococcus aureus (MRSA) drug market will be driven in part by ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.